Streetbeat News

Regulatory

EIS

SPY

USO

President Biden has called on Egypt and Qatar to pressure Hamas into negotiating a hostage deal with Israel, according to a senior administration official cited by AP.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:13 pm

CLOV

Clover Health Investments Corp (CLOV) received a notice from Nasdaq on April 2 regarding a delisting or failure to satisfy a continued listing rule or standard, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:10 pm

NBSE

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) received a notice from Nasdaq on April 4, 2024, for not complying with the continued listing requirements due to its failure to timely file its Annual Report for the fiscal year ended December 31, 2023. The company has until June 3, 2024, to submit a compliance plan, with a potential extension until September 30, 2024, to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:09 pm

SOND

Sonder Holdings Inc. (NASDAQ:SOND) received a deficiency notification from Nasdaq for not filing its Annual Report on Form 10-K for the year ended December 31, 2023, on time. The company has 60 days to submit a compliance plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), with a possible extension of up to 180 days. Sonder intends to submit this plan and work diligently to file the overdue report as soon as practicable.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:06 pm

NXU

Nxu Inc. received a notice from Nasdaq on April 2, indicating that the company is not in compliance with the $1.00 minimum bid price requirement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:02 pm

TGS

Transportadora De Gas Del Sur (TGS) shares are experiencing an uptick due to overall strength in the energy sector. The company has also announced a new agreement with ENARGAS for a temporary adjustment in natural gas transportation tariffs, which includes a monthly adjustment formula starting in May.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:56 pm

OCGN

Ocugen, Inc. (NASDAQ:OCGN) shares rose after announcing approval to proceed with medium dose dosing in the Phase 1/2 study of OCU410. The Data and Safety Monitoring Board for the ArMaDa clinical trial approved this next step, highlighting the therapy's safety and potential as a one-time treatment for life. Ocugen also updated on progress in its gene therapy programs for blindness diseases. The company's stock is up 20%, trading at $1.81.

Portfolio Pulse from Erica Kollmann

April 05, 2024 | 7:56 pm

SPY

President Biden has committed his administration to ensuring that those responsible for the Baltimore Bridge collapse will bear the costs of repairing the damage. This statement underscores the government's stance on accountability for infrastructure failures.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:34 pm

AZN

The FDA has granted accelerated approval to ENHERTU, a treatment for unresectable or metastatic HER2-positive solid tumors. This decision could significantly impact the drug's availability and use in treating various cancers, marking a pivotal development for patients with these conditions.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:30 pm

DJT

Trump Media & Technology Group's shares are trading lower following its Nasdaq debut, amid calls by Democrats for an inquiry into alleged influence peddling.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 6:31 pm